Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.
Level 5 - mechanism / opinion, no new human data
Narrative review describing biological mechanisms without systematic review methodology or new human data
PubMed 39114288 · doi:10.3389/fendo.2024.1431292
What was done
Narrative review synthesizing the cellular mechanisms of action, downstream signaling pathways, and therapeutic applications of glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists for metabolic disease.
What was found
The abstract reports qualitative physiological mechanisms and provides no quantitative data. GIP and GLP-1 stimulate central satiety centers and pancreatic beta-cell insulin secretion. They exert divergent effects on alpha-cell glucagon production: GIP is glucagonotropic during hypoglycemia, whereas GLP-1 is glucagonostatic during hyperglycemia. GIP directly stimulates lipogenesis and GLP-1 indirectly promotes lipolysis, working together to maintain healthy adipocyte function, reduce ectopic fat distribution, and increase adiponectin secretion.
Why it matters
Explains the complementary physiological actions of dual GIP/GLP-1 receptor co-agonism in glycemic control, weight management, and cardiovascular risk reduction in type 2 diabetes and obesity.
Limits
Narrative review design lacking systematic search methodology, meta-analytic pooling, or new empirical data. The abstract contains no quantitative effect sizes, clinical trial outcome numbers, or sample sizes.
Cited by
- supports In non-diabetics, blood sugar levels do not drop very low when taking GLP-1 receptor agonists.